Last reviewed · How we verify
NCT01896778
Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer
NA trial testing Hyperthermia Treatment in Adult Liver Carcinoma in 9 participants. Completed in 23 February 2018.
23 February 2018
Quick facts
| Lead sponsor | Roswell Park Cancer Institute |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 9 |
| Start date | 4 October 2013 |
| Primary completion | 23 February 2018 |
| Estimated completion | 23 February 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Hyperthermia Treatment
- Laboratory Biomarker Analysis — full drug profile →
Conditions studied
- Adult Liver Carcinoma — all drugs for Adult Liver Carcinoma →
- Breast Carcinoma — all drugs for Breast Carcinoma →
- Colon Carcinoma — all drugs for Colon Carcinoma →
- Kidney Neoplasm — all drugs for Kidney Neoplasm →
Sponsor
Roswell Park Cancer Institute
Who can join
18 and older, any sex, with Adult Liver Carcinoma or Breast Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized pilot clinical trial studies body warming in improving blood flow and oxygen delivery to tumors in patients with cancer. Heating tumor cells to several degrees above normal body temperature may kill tumor cells.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01896778
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Hyperthermia Treatment
Trials testing the same drug.
- NCT03955640 — Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences · Phase 1 · terminated
- NCT02899221 — Hyperthermia and High Dose Rate Radiation Therapy in Treating Patients With Recurrent Prostate Cancer After Radiation · NA · completed
Other Roswell Park Cancer Institute trials
Trials by the same sponsor.
- NCT07489287 — GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer · Phase 1 · not yet recruiting
- NCT06943664 — Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-I · Phase 2 · not yet recruiting
- NCT06827054 — Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids · Phase 2 · not yet recruiting
- NCT06334016 — Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream · EARLY_PHASE1 · not yet recruiting
- NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma · Phase 1 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01896778 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Roswell Park Cancer Institute
- Last refreshed: 25 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01896778.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing